Targeted photoimmunotherapy method for selectively inhibiting ABC transporters in multidrug-resistant cancer cells

This technology uses a light-activated antibody-drug conjugate to selectively target and disable drug resistance pumps in cancer cells, improving chemotherapy effectiveness while minimizing harm to healthy tissue.

Background

Chemotherapy is a cornerstone of cancer treatment, but its effectiveness is frequently limited by multidrug chemoresistance. This challenge is devastating in metastatic cancers—such as ovarian, pancreatic, and colorectal—where up to 90 percent of recurrent cases resist standard treatments. A primary driver of this resistance is the overexpression of proteins known as ATP-binding cassette (ABC) transporters, particularly P-glycoprotein. These proteins act as cellular efflux pumps, actively ejecting chemotherapeutic drugs from cancer cells before the medication can take effect. Consequently, there is a critical clinical need for strategies that neutralize these pumps, retaining therapeutic drugs inside tumors to restore treatment efficacy.

Despite the clear need to disable these efflux pumps, current therapeutic approaches have largely failed in clinical settings due to severe safety limitations. Traditional small-molecule inhibitors designed to block P-glycoprotein have proven unsuccessful because they lack tumor selectivity, indiscriminately affecting healthy cells and causing unacceptable systemic toxicity. Similarly, conventional photodynamic therapies that use light-activated compounds to damage these transporters suffer from the same fundamental flaw. Without a mechanism to specifically target only cancerous cells, these agents distribute broadly, leading to significant off-target damage in healthy tissues.

Technology

This photoimmunotherapy platform utilizes a specialized conjugate connecting a cancer-targeting antibody with a light-activated molecule. The antibody specifically binds to cancer cells overexpressing a certain protein receptor. Once absorbed, a specific wavelength of light is applied to the area, activating the conjugate to generate reactive oxygen. This causes highly localized cellular disruption that disables the cellular pumps cancer cells use to expel chemotherapy drugs. By shutting down these transporters, the therapy traps therapeutic drugs inside the cells, breaking down their primary defense mechanism.

This technology stands out by overcoming the severe limitations of traditional approaches to multidrug-resistant cancers. Historically, drugs designed to block these cellular pumps failed due to high systemic toxicity and an inability to distinguish between healthy and cancerous tissues. In contrast, this approach provides unique dual selectivity. First, the antibody ensures the conjugate accumulates primarily in targeted tumor cells. Second, the therapeutic effect only occurs where the activating light is applied. This controlled, two-step activation prevents collateral damage to surrounding healthy tissue. By physically disabling the pumps through localized light activation rather than systemic chemicals, it offers a safer, highly targeted strategy to reverse chemotherapy resistance.

Benefits

  • Overcomes multidrug resistance by functionally inhibiting ABC transporters (such as P-gp), significantly increasing the retention and efficacy of chemotherapeutic agents inside cancer cells.
  • Minimizes systemic toxicity and off-target effects through a dual-selectivity mechanism that relies on both EGFR-targeted delivery and localized light activation.
  • Evades active tumor efflux mechanisms prior to activation, ensuring higher accumulation of the therapeutic conjugate within chemoresistant cells compared to free photosensitizers.
  • Integrates seamlessly into existing clinical workflows, allowing for targeted intraoperative light activation during procedures like cytoreductive surgery.
  • Offers a highly adaptable platform that can be customized to target different tumor antigens or other resistance-driving transporters (e.g., ABCC1, ABCG2) across various cancer types.
  • Demonstrates strong translational viability with a sterile-filterable formulation that maintains high purity and photoactivity without causing acute in vivo toxicity.

Applications

  • Treating multidrug-resistant cancers
  • Enhancing chemotherapy drug retention
  • Intraoperative cancer photoimmunotherapy
  • Treating peritoneal cancer metastasis
  • Targeting EGFR-overexpressing tumors

Additional info

This technology utilizes an EGFR-targeted photoimmunoconjugate synthesized via carbodiimide chemistry, linking cetuximab to a benzoporphyrin derivative. Upon 690 nm light activation, the conjugate generates reactive singlet oxygen, causing localized photodamage that functionally inhibits ABC transporters like P-glycoprotein. By disrupting plasma membranes or depleting ATP, this method neutralizes efflux pumps, increasing the intracellular retention and efficacy of chemotherapeutic agents in multidrug-resistant cancer cells while minimizing off-target toxicity.